Human acute myeloid leukemias (AMLs) are sustained by leukemic stem cells (LSCs) that generate through aberrant differentiation the blast cells that make up the bulk of the malignant clone. LSCs were first identified as rare cells with an immunophenotype shared with normal hematopoietic stem cells (HSCs). However, refinements of xenotransplantation assays, alternative methods of quantitation and syngeneic murine models have all led to an appreciation that LSCs display marked variability in frequency, immunophenotype and differentiation potential, both between and even within leukemias. Insights from next-generation sequencing efforts have dramatically extended understanding of the mutational landscape and clonal organization of AML and have added an additional layer of complexity to the biology of LSCs: a requirement to consider the effect of the various recurrently occurring genetic lesions in AML on the initiation and maintenance of leukemic subclones. Despite these advances, cure rates in AML remain substantially unchanged in recent years. A renewed focus on the biological properties of chemotherapy-resistant LSCs, a cellular entity of prime clinical importance, will be required to develop additional therapeutic strategies to enhance patient outcomes.
INTRODUCTION
Normal mammalian hematopoiesis is organized as a cellular hierarchy sustained at its apex by a rare population of hematopoietic stem cells (HSCs), accounting for approximately 1 in 10 4 nucleated bone marrow cells in the example of the inbred mouse. These cells have a capacity both to self-renew for towards the lifetime of the animal and to generate through differentiation cells of the various distinct lineages found in normal blood. [1] [2] [3] [4] In malignancies involving the myeloid lineage, the concept of the malignant stem cell, or leukemia stem cell (LSC), is well supported by a wealth of observational and experimental data. However, as will be discussed, the biological properties of these cells vary with regard to immunophenotype, transcriptome, genetics, cell cycle status and multilineage differentiation potential. It would seem that there are many types of cell that fulfill the chief criterion for an LSC: a single cell with the potential to generate a malignant clone of sufficient size to cause disease.
FREQUENCY AND PHENOTYPE OF STEM CELLS IN AML
Studies in acute myeloid leukemia (AML) have perhaps led the way in establishing the concept of the LSC. Early in vitro work revealed that only a small minority of blasts (typically 0-1%) formed colonies when cultured in semisolid medium, with considerable variation in frequencies between samples. 5, 6 Colonies that did form exhibited varying capacities for continued proliferation upon serial replating. 6, 7 Use of monoclonal antibodies followed by complement lysis of antibody-bound cells further revealed that AML colony-forming cells (CFCs) exhibit an immunophenotype that is often somewhat distinct from that of the general blast population, with HLA-DR and CD33 typically being expressed on a higher proportion of CFC than bulk AML cells and vice versa for the late myeloid differentiation markers CD11b and CD14. 8 Importantly, despite the significant phenotypic differences between samples from different patients, the bulk blast population in almost all of the 20 cases analyzed expressed one or more late myeloid differentiation antigens (e.g. CD11b, CD14 or CD15) not expressed on AML-CFC. 8 These data, which demonstrated that cells within the AML clone are functionally and immunophenotypically heterogeneous, gave weight to the hypothesis that leukemic hematopoiesis is hierarchically organized in a manner similar to normal hematopoiesis: an apical population of LSCs and progenitors generates through a 'forme fruste' of differentiation progeny with progressively lower, or absent, proliferative potentials. 6 The hypothesis received further support from the results of early xenotransplantation experiments: phenotypically immature CD34 þ CD38 À AML blasts from multiple patients reconstituted leukemic hematopoiesis in non-obese diabetic/severe-combined immunodeficiency mice, whereas phenotypically more mature CD34 þ CD38 þ subpopulations failed to engraft. 9 Limiting dilution transplantation experiments suggested that, as is the case for normal HSC versus normal clonogenic progenitor cells, cells capable of initiating leukemic hematopoiesis in a mouse were considerably less frequent than AML-CFC, with frequencies in the range 1 in 10 4 to 1 in 10 7 . 9 Although these severe-combined immunodeficiency leukemia-initiating cells do not necessarily induce disease in the transplant recipient, the xenograft assay is widely viewed as a pragmatic surrogate for reading out human AML cells with LSC potential. The resulting model for leukemic hematopoiesis, whereby the bulk of the clone is sustained by a small population of LSCs, suggested that AML LSCs were very similar to normal HSCs: rare, phenotypically immature and, based on chemoresistance, presumably quiescent.
conclusions drawn. In early in vitro studies different methods of culture of AML blasts produced strikingly different results. For example, the addition of phytohemagglutinin to the normal leukocyte feeder cells within the lower agar layer of AML blast cultures resulted in AML-CFC being identified in 80-90% of tested samples, albeit at low frequencies, as opposed to 30-40%, presumably by increasing the concentrations of growth factors in the culture. 10, 11 More recently, use of recombinant cytokines, modern cell culture media and fresh blasts revealed that up to 9% of myeloblasts exhibit AML-CFC potential in semisolid culture in primary human MLL-translocated samples. 12 Likewise, refinements of the in vivo model have resulted in enhanced levels of engraftment of transplanted cells and enhanced detection of LSCs. These have included use of more profoundly immunodeficient non-obese diabetic/severe-combined immunodeficiency mice, such as those engineered to lack a functional IL2-Rg chain (non-obese diabetic/severe-combined immunodeficiency Il2rg À / À , NSG), which results in a stable lack of natural killer (NK) cell activity;
13,14 use of anti-CD122 pre-treatment of xenograft recipients to target NK cells; 15 use of neonatal versus adult NSG mice; 16 and use of humanized NSG mice constitutively expressing human versions of interelukin-3, stem cell factor and granulocyte/ macrophage colony-stimulating factor. 17 Despite these adaptations, which have led to recent reports of cases of human AML with LSC frequencies of as high as 1 cell in 500, 18 it remains the case that only around 50% of AML cases will engraft mice at all, with these typically generating only modest levels of human:mouse chimerism (e.g. 0.1-10% of host bone marrow). 19, 20 Attempts to xenoengraft cells from patients with acute promyelocytic leukemia, AML with t(8;21) and AML with inv(16) mostly fail, 18, 20, 21 suggesting that immunodeficient mice may not be able to detect LSCs at all in certain molecular subtypes of AML. In addition, while the recently confirmed heterogeneity of apparent LSC frequencies in human AML 18, 22 likely reflects real differences in the biology of the disease (a supposition supported by the positive correlation of therapeutic failure with xenoengraftment potential), 20 it also seems probable that immunodeficient mice generally under-report the true frequency of LSCs in other molecular subtypes because of cross-species differences, such as the absence of human versions of soluble and membrane-bound factors in the murine bone marrow microenvironment. This point is exemplified by xenograft studies in primary Philadelphia-positive acute lymphoblastic leukemia (ALL): using copy number variation as a method to track ALL clones, it was often the case that minor subclones from the patient at diagnosis gave much more robust engraftment by comparison with the major one, demonstrating that the murine microenvironment may selectively support expansion of genetically distinct subclones. 23 Studies from syngeneic mouse models of AML are informative because issues relating to the cross-species barrier, which may represent a significant obstacle to human LSC homing and engraftment, are negated. Limit dilution analyses of AML cells from a murine retroviral transduction and transplantation model of human MLL-AF9 AML suggested LSC frequencies of 0.3-1% in unsorted bulk AML cells, 24, 25 substantially higher than any LSC frequency reported from xenoengraftment studies. However, further refinement of the method used to detect LSCs in this model led to the conclusion that they were even more frequent. When AML-CFCs were individually isolated, expanded briefly in culture and their progeny secondarily transplanted, in every case AML resulted, suggesting both that the true frequency of LSC in the model was 1 in 4 cells and that AML-CFC exhibited LSC potential. 24 Thus, even in the setting of a syngeneic transplantation system, use of an alternate method to limit dilution analysis led to the conclusion that LSCs were more frequent than considered previously. Frequent LSCs have also been reported in an SPI1 knockout model where transplantation of as few as 10 AML cells was able to fully recapitulate leukemia in 75% of cases. 26 These examples show that, at least in mouse models of human AML, the frequency of LSCs can be very high.
Murine models have also shown that LSC frequencies may vary between different AML molecular subtypes, as in human AML. For example, they are significantly more frequent in murine leukemias associated with MLL-AF9 or MLL-ENL by comparison with those associated with MLL-AF10, MLL-AF1p or MLL-GAS7, 27 whereas in leukemias initiated by retroviral overexpression of Meis1 and Hoxa9, LSC frequencies varied dramatically, ranging between 0.3 and 71% of cells within the clone despite similar morphological appearances of the leukemias. 28 Not all murine AMLs generate leukemias with frequent LSCs, however. For example, in Pten À / À AML only 1 in 6 Â 10 5 cells was able to transplant disease. 29 One additional and important caveat to the use of murine models, in particular genetic knock-in lines, is that the leukemia-initiating oncogene may be expressed in the entire stem and progenitor compartment, in contrast to the situation in humans where disease is initiated following sequential acquisition of mutations targeting a single cell and its progeny. Nevertheless, taken together, these data suggest that the LSC frequencies vary between leukemias of different molecular subtypes ( Figure 1a ) and may be significantly underestimated by methods involving transplantation.
Reflecting the differing frequencies of LSCs in AML, their immunophenotypes also appear quite variable. This might have been predicted from early studies of in vitro cultured AML-CFC. Again using complement lysis of antibody-bound cells, AML samples could be categorized into three distinct groups: those where the clonogenic cells exhibited an early immunophenotype most similar to that of normal granulocyte/erythroid/megakaryocyte/macrophage colony-forming units, those exhibiting an intermediate phenotype most similar to early granulocyte/ macrophage colony-forming units and those with a mature immunophenotype most similar to late granulocyte/macrophage colony-forming units ( Figure 1b) . 8, 30 Likewise, refinement of xenoengraftment protocols has led to the detection of LSCs in AML populations with variable phenotypes downstream of the CD34 þ CD38 À profile shared with normal HSCs. Thus, AML cells expressing CD38 (cyclic ADP ribose hydrolase), CD45RA (protein tyrosine phosphatase receptor, type C, RA isoform), CD32 (low-affinity immunoglobulin g Fc receptor IIb), CD25 (IL-2 receptor a chain) or lineage markers, or lacking expression of the transmembrane sialomucin CD34, have all been shown to initiate leukemic hematopoiesis following transplantation into immunodeficient mice. 15, 22, [31] [32] [33] [34] [35] [36] [37] This contrasts with the earlier notion that LSCs were exclusively associated with a Lin
Indeed, LSCs of variable immunophenotypes coexist in individual patients. 36, 37 It is of note that the most refined immunophenotype of normal human HSCs presented to date (
suggests that all LSCs may reside phenotypically downstream of normal HSCs based on their lack of expression of CD90. 32 Similarly in syngeneic murine models of human MLL-translocated AML, most LSCs express CD11b and Gr1, markers that are characteristic of mature myeloid lineage cells, placing them phenotypically downstream of HSCs and even granulocyte/macrophage progenitor cells (GMP). 24 
could be identified, each with a capacity to regenerate LSCs of the other phenotypes. 40 Taken together, the experimental findings are consistent with a general model for leukemic transformation whereby the property of self-renewal (at its simplest, an ability to proliferate without undergoing differentiation) becomes associated with cells that exhibit the immunophenotypic characteristics of normal non-self-renewing cells downstream of the HSC. This may occur either through the sequential acquisition of mutations in the HSC, which have the consequence of generating a self-renewing LSC with a downstream progenitor phenotype (as may occur in the example of myeloblastic transformation of chronic myeloid leukemia), 41 or through the direct leukemic transformation of a non-self-renewing downstream cell (as may be experimentally demonstrated by targeting expression of MLL-ENL, MLL-AF9 or MOZ-TIF2 to GMP cells). 25, [42] [43] [44] Furthermore, the murine model of human MLL-AF9 AML illustrates that leukemia oncogenes may couple self-renewal to other properties of downstream progenitor cells, such as their cell cycle status. Here, for example, LSCs are actively proliferating cells and not quiescent. 27 
MULTILINEAGE DIFFERENTIATION POTENTIAL OF HUMAN AML LSC
Normal HSCs are characterized by their multilineage differentiation potential (Figure 2a) . [1] [2] [3] [4] Similarly, in chronic myeloid leukemia (CML), the LSC also exhibits multilineage differentiation, as demonstrated by techniques such as X-chromosome inactivation pattern (XCIP) analysis, karyotype analysis and polymerase chain reaction (PCR) for the BCR-ABL oncogenic fusion. These approaches have demonstrated that mature granulocytes, monocytes, erythrocytes, platelets and B lymphocytes in CML patients are all part of the malignant clone; 45, 46 the T-lymphocyte lineage may also be variably involved. 47 A study of patients with chronic myelomonocytic leukemia associated with a mutant RAS allele yielded similar conclusions: mutant KRAS or NRAS was identified in granulocytes, monocytes, B lymphocytes and T lymphocytes, indicating the presence of a multipotent LSC. 48 In myelodysplasia, a multipotent malignant stem cell is implied by the observation of clonal hematopoiesis, as determined by XCIPs, in a cellularly heterogeneous bone marrow in patients with refractory anemia (RA), RA with ringed sideroblasts or RA with excess blasts. 48 In human AML, evidence also shows multilineage involvement in many but not all cases. Use of radiolabeled iron chloride incorporation demonstrated that erythroid progenitors from three patients with AML exhibited the same abnormal karyotype found in myeloblasts. 49 Likewise, use of immunophenotyping demonstrated that erythroid progenitors shared an abnormal karyotype (e.g. monosomy 7 or trisomy 8) with myeloblasts in 75% of the patients studied, and megakaryocyte progenitors were part of the malignant clone in at least 17% of cases. However, multilineage involvement was not seen in every case: other samples only showed granulocytic/monocytic lineage involvement (as illustrated in Figure 2b) . 50 The presence of an LSC with multilineage differentiation potential may also be inferred from the observation of the multilineage dysplasia that is characteristic of AML associated with inv(3) or t(3;3), t(6;9) or NPM1 mutations. 51 Thus, there is evidence that some myeloid leukemias are associated with LSCs that exhibit multilineage differentiation, whereas others are associated with LSCs that exhibit a more lineage-restricted pattern of differentiation.
There are two interpretations for the observation of multilineage involvement in AML, which are not mutually exclusive. On the one hand, the pool of LSCs may be relatively uniform and stably multipotent, analogous to the LSCs in CML, but skewed towards the production of malignant myeloblasts (Figure 2c) . 8 BFU-E, burst-forming unit erythroid; CFU-E, colony-forming unit erythroid; CFU-GEMM, granulocyte/erythroid/megakaryocyte/macrophage colony-forming unit; CFU-GM, granulocyte/ macrophage colony-forming unit; CFU-Meg, megakaryocyte colony-forming unit; Monos, monocytes; Neuts, neutrophils.
Alternatively, initiating mutations in a normal HSC may establish one or more pre-LSCs (defined as a single cell with a capacity to generate a stable long-term clone that does not result in disease) or a myelodysplastic LSC, all of which retain multilineage differentiation potential. Only upon the acquisition of further mutations or epigenetic changes does the initiated clone evolve to produce a subclone of lineage-restricted malignant myeloblasts driven by full-fledged LSCs (Figure 2d) . Consistent with the first interpretation is the observation that, following chemotherapy, most patients who achieve morphological remission return to a state of polyclonal hematopoiesis (as determined by XCIPs), 52 although it is possible that chemotherapy simultaneously eradicates all pre-LSCs and LSCs. However, a number of examples support the latter interpretation. Following treatment, some patients exhibit a clonal morphological remission. 53 Although the phenomenon is not as frequent as first thought, 52, 54 where convincingly present it is typically associated with features of myelodysplasia, 55, 56 suggesting that chemotherapy eradicated the AML LSC subclone but not the myelodysplastic syndrome (MDS) LSC founder clone. Likewise, comparison of the clonal relationship between mature granulocytes and myeloblasts isolated from patients with AML, using analysis of XCIP, karyotype (e.g. monosomy 7 or trisomy 8) or immunoglobulin gene rearrangements, demonstrated that the mature granulocytes were part of the malignant clone in five patients studied, 57 although here the possibility that the malignant myeloblasts retain a capability to differentiate into mature granulocytes, as is observed in mouse models of MLL-translocated AML, 27 cannot be excluded.
Evidence that a full-fledged LSC clone may emerge from a pre-LSC clone is also supported by elegant work where apparently phenotypically normal residual HSCs were separated from FLT3-mutated AML LSCs in the bone marrow samples of patients at diagnosis. The basis of the separation was a Lin À CD34 þ CD38 À phenotype, which was additionally negative for expression of putative LSC-specific markers HAVCR2 (also known as TIM3) and CD99. 58 Although PCR confirmed wild-type FLT3 status in the sorted HSCs, some nevertheless exhibited AML-associated mutations such as those in TET2, NPM1, SMC1A and SKP2. Transplantation of sorted preleukemic HSCs into immunodeficient mice demonstrated the ability of TET2 mutant HSCs to generate multilineage engraftment, suggesting that at presentation patient bone marrow contains a mixture of normal HSCs, TET2 mutant pre-LSCs as well as TET2 FLT3 double-mutant full-fledged LSCs. In keeping with their apparent role in establishing a pre-LSC that retains multilineage differentiation potential,
59
TET2 mutations have recently been identified in 5% of elderly women with clonal hematopoiesis, as determined by XCIPs, even though their blood counts were normal. 60 Another example comes from studies of patients with AML with t(8;21). In diagnostic samples, RUNX1-RUNX1T1 transcripts were detected in erythroid progenitors, megakaryocyte progenitors and B lymphocytes, as well as in the bulk blast population and AML-CFCs. 61 In most remission patients, rare CD34 þ CD38 À CD90 þ Lin À HSCs, mature monocytes and B lymphocytes, but not T lymphocytes, continue to express RUNX1-RUNX1T1 transcripts (e.g. 1 in 10 4 cells), indicating persistence at low level of a preleukemic clone following therapeutic eradication of the disease-inducing AML LSC clone. 61 These and other studies support the concept in AML of a multistep pathway to malignancy, with each genetic mutation (or indeed epigenetic change) generating pre-LSCs or LSCs that exhibit varying capacities to self-renew, differentiate, remain quiescent, proliferate, evade immune surveillance and avoid apoptosis.
INSIGHTS FROM HIGH-THROUGHPUT SEQUENCING
Recent studies making use of next-generation DNA sequencing have generated important insights, particularly with regard to the number of genetically related clones present at diagnosis, progression and relapse. Although early studies extended the repertoire of driver mutations in AML, for example, those in IDH1 and DNMT3A, [62] [63] [64] [65] investigations of clonality have been made possible by a two-step sequencing and mutation confirmation approach. In the first step, whole genome sequencing of both malignant cells and a paired non-malignant tissue sample (e.g. skin) to approximately 25-fold genome coverage is performed. This permits the identification of somatic events and their classification into tiers according to whether they occur in protein coding sequences, splice sites or non-coding RNAs (Tier 1), conserved or regulatory genome sequences (Tier 2), non-coding regions (Tier 3) or repetitive non-coding regions (Tier 4). In the second phase, candidate mutations from Tiers 1 to 3 are validated using hybridization capture, which, critically, provides up to 1000-fold coverage of the mutated site, which allows accurate determination of the mutant allele burden. The identification of all somatic events in paired presentation and relapse AML samples or paired MDS and AML samples, together with mutant allele frequencies, permits deductions to be made with regard to the genetic relationship of the leukemia clones. 66, 67 In seven patients with AML associated with a normal karyotype, the median number of genetically related but distinct clones of sufficient size to be detected by this method (i.e. accounting for more than 2-3% of bone marrow cells) was 3 (range 1-4) at presentation and 2 (range 1-3) at relapse. 66 As has been reported in pediatric ALL, 68 all relapse clones were genetically related to founder clones in the presentation samples, but were variably derived from either the major clone at presentation or from a more minor one. In each case, relapse clones gained relapse-specific mutations, including an excess of transition mutations likely induced by chemotherapy, although it currently remains unclear as to whether these novel mutations contribute to relapse or to the chemoresistance of the relapsed clone in AML. 66 Evidence from studies in ALL suggests that possibility because 10% of B-ALL 69 and 19% of T-ALL 70 relapse samples exhibit mutations that enhance the activity of the purine 5 0 -nucleotidase NT5C2, thereby conferring partial resistance to nucleoside analog chemotherapy drugs that form a therapeutic mainstay. Again though, it is not as yet uniformly clear whether these mutations were induced by chemotherapy or were pre-existing before chemotherapy in a low-level subclone.
Studies in MDS have confirmed that the great majority of unfractionated bone marrow cells are clonal, even when the blast count was o5%, 67 in keeping with an MDS LSC with multilineage differentiation potential. Whole genome sequencing was performed on seven pairs of patient samples; patients had presented with either RA (two patients) or RA with excess blasts (five patients) and each went on to develop AML after 1 to 22 months. Importantly, the MDS sample was unenriched, whereas the comparator AML sample was enriched for blast cells by flow sorting for a CD45 þ /SSC lo population. The median number of genetically related but distinct clones of sufficient size to be detected was 2 (range 1-4) in MDS bone marrow and 2 (range 2-4) at progression to AML. 67 In each case, the development of AML was associated with either the appearance of one or more clones genetically related to the MDS founder clone but exhibiting new mutations, or the expansion of one or more clones already present in the MDS sample. The appearance of mutations in genes such as WT1, RUNX1 and PTPN11 was associated with progression to AML in some cases, although additional studies will be required to more fully delineate the range of mutations associated with evolution of MDS to AML. 67 Progression to AML in a single patient with severe congenital neutropenia was also evaluated by high-throughput sequencing, making use of archived patient material. Mutations in 12 genes including CSF3R, LLGL2, ZC3H18, ASXL1, RUNX1, EP300 and SUZ12 were identified in the AML sample, whereas analysis of a bone marrow sample from 15 years earlier identified only the first three of these, suggesting that acquisition of the latter mutations was critical in the evolution of a full-fledged LSC clone. 71 In another study, a median of 1.5 clones per AML was observed in AML M1 (range 1-2) and 2 (range 1-4) in acute promyelocytic leukemia, with an average of 10 mutations with translational consequences per genome for each. 72 Interestingly, the total number of somatic mutations in the AML samples studied increased with age. When normal progenitor cells from individuals of different ages were analyzed by exome sequencing, a similar pattern was observed. This implies that most somatic events detected by high-throughput sequencing methods are random, pre-existing background mutations that accumulate with age and that perhaps only two to four driver mutations are required to develop AML. 72 In keeping with this, in one case the only mutations to be detected that are recurrently found in AML were PML-RARA and FLT3. This fits with a two-hit model of leukemogenesis, which posits the stepwise acquisition and collaboration between Class 1 mutations that activate signal-transduction pathways to confer a survival or proliferative advantage (e.g. mutations in FLT3, RAS or KIT) and Class 2 mutations in genes coding for transcriptional regulators that potentially impair differentiation (e.g. generation of novel oncogenes such as RUNX1-RUNX1T1 or PML-RARA, or mutations in CEBPA or NPM1).
73 While serving as a useful schematic this model may be incomplete. For example, Class 1 mutations can only be identified in B50% of cases of AML 74 and are not necessarily part of the founder clone. For example, in the first AML genome sequenced, mutant FLT3 was identified in only 70% of the cells, indicating its presence in the major subclone but not the founder clone, and NRAS or FLT3 mutations may appear de novo at relapse or disappear having been present at diagnosis. 62, 75, 76 These high-throughput sequencing studies emphasize that myeloid malignancies are typically oligoclonal at presentation, at least with regard to the number of distinct genetic clones accounting for more than 2-3% of cells, which is in keeping with observations in ALL. 23, 77 CLINICAL CORRELATES AND FUTURE DIRECTIONS The data suggest that the biological properties of AML LSC are heterogeneous. They may have immature or mature immunophenotypes, be multipotent or lineage restricted, frequent or uncommon, quiescent or cycling. One clinical observation, based on the assumption that all AML clones are sustained by a population of LSCs, is that current chemotherapy protocols successfully eradicate LSCs in a significant proportion of patients, that is, the 30-40% of patients that are cured (typically with cyclical therapy with daunorubicin and cytarabine). [78] [79] [80] Thus, some LSCs are chemosensitive and others chemoresistant. Clearly, the critical cellular entity deserving of further research is the chemoresistant LSC, because it is only through successful targeting of these cells that cure rates will improve.
It has been assumed that LSCs survive chemotherapy because of quiescence and this is supported by the observation that treatment of human AML cells with 5-fluorouracil eradicates AML-CFC activity but not all LSC activity. 81 Although the use of 3 H-thymidine suicide assays demonstrated that a median of 59% (range 24-87%) of AML-CFCs in 15 patient samples were in the S-phase of the cell cycle, 82 nearly all CD34 þ CD38 À AML cells appear to be in G 0 based on DNA content analysis and Ki-67 immunostaining, albeit with some interpatient variability. 33, 83 Interestingly, in a separate study, incubation of seven samples of AML blasts with 3 H-thymidine reduced the frequency of AML-CFCs and their long-term culture-initiating cell counterparts by medians of 61% (range 19-99%) and 50% (range 0-99%), respectively, whereas LSCs were reduced to a lesser extent by a median of 26% (range 0-82%). 84 These data are in keeping with the concept that LSCs are typically more quiescent than AML-CFCs, but they also highlight some considerable heterogeneity between patient samples. Countering the argument that LSCs are always quiescent, in one sample with a normal karyotype, 80% of LSC activity was eradicated by 16-h incubation with 3 H-thymidine, indicating that human LSCs may also be in the active phase of the cell cycle. Furthermore, important differences in the depth of quiescence may exist in general between LSCs and normal HSCs: culture of G 0 AML blasts from three patients in liquid culture, even without growth factors, led to the transition of the great majority to G 1 or SG 2 M within 24 h, whereas similarly cultured normal HSCs remained profoundly quiescent. 84 Thus, although quiescence may be one important way in which LSCs evade cytotoxic chemotherapy, other potential mechanisms are likely to be in operation, such as the expression of drug efflux pumps, impaired apoptotic mechanisms and efficient DNA damage repair. For example, data from mouse models show that MLL-translocated LSCs are both cycling 27 and chemoresistant. 85 Understanding the mechanisms by which LSCs evade chemotherapy remains an important priority in AML research.
Strategies for targeting chemoresistant LSC, both established and more novel, are beneficial. Bone marrow transplantation is effective not just because of the ability to deliver intensive chemoradiotherapy as part of the treatment protocol. A significant portion of its efficacy derives from a graft-versusleukemia effect, which is presumably consequent upon the activity of the donor immune system versus residual LSC. 86 Reflecting this, one mechanism of therapeutic failure following haploidentical bone marrow transplantation is through acquired uniparental disomy of chromosome 6p, which codes for the human leukocyte antigen complex. 87 More recently, the calicheamicin-conjugated anti-CD33 monoclonal antibody gemtuzumab ozogamicin, which targets an antigen expressed by LSC and AML-CFCs, 8, 88 delivered with chemotherapy has been shown to increase modestly cure rates in patients with intermediate-or good-risk subtypes of AML. 89, 90 Other investigational agents, such as anti-CD47 antibody therapy, may prove promising. Differential expression of CD47, which acts as a negative regulator of macrophage-mediated phagocytosis via interaction with signal regulatory protein a, can distinguish normal HSCs from LSCs, it being more highly expressed on the latter, and so may represent a selective target. 91 Other markers more highly expressed on LSC than normal HSC include CD96, a member of the immunoglobulin gene superfamily, 92 CLL1 93 and HAVCR2 (TIM3), 94 and these too may prove promising targets.
Although considerable advances have been made in identifying the biological properties of AML LSCs, many questions remain. Now that the list of recurrently occurring genetic lesions in protein coding genes AML appears nearly complete, 95 we remain a long way from understanding the biological consequences of each one for normal hematopoiesis, how each contributes to the initiation and maintenance of the evolving pre-LSC or LSC or how mutations collaborate to induce or sustain expression of the stem-like genetic programs characteristic of LSCs. 25, 27, 36 Further, for some recently discovered mutations, it remains unclear which are initiating in nature and typically identified in founder clones (and therefore potentially good therapeutic targets) and which are leukemia promoting in nature, as seems to be the case for FLT3 mutations (and perhaps less likely to be promising therapeutic targets). It is also not clear how normal HSCs are outcompeted by AML clones: do the latter directly or indirectly repress proliferation of the former? Above all, given that the standard treatment of most types of AML has not changed significantly since the 1970s 78 in contrast to developments in other types of hematological malignancy such as CML, myeloma and some types of lymphoma, how can we do better?
